Quetiapine fumarate (Seroquel®): A new atypical antipsychotic

Drugs of Today

Volumn 35, Issue 3, 1999, Pages 193-210

  Goldstein, Jeffrey M ^a,b  

^a Zeneca Pharmaceutical   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; VERTIGO;

EID: 0032937396     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.3.533849     Document Type: Review

References (76)

1. Dixon, L.B., Lehman, A.F., Levine, J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 1995, 21: 567-77.
2. Buckley, P.F. Treatment of schizophrenia: Let's talk dollars and cents. Am J Managed Care 1998, 4: 369-83.
3. Casey, D.E., Keepers, G.A. Neuroleptic side effects: Acute extrapyramidal syndromes and tardive dyskinesia. In: Psychopharmacology: Current Trends. Casey, D.E., Christensen, A.V. (Eds.). Springer: Berlin 1988, 74-93.
4. Woerner, M.G., Alvir, J.M.J., Saltz, B.L., Lieberman, J.A., Kane, J.M. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors. Am J Psychiatry 1998, 155: 1521-8.
5. Dickson, R.A., Gupta, S. Antipsychotic-induced hyperprolactinemia causes serious adverse effects. J Psychotic Disord 1997, 2: 3-17.
6. McEvoy, J. New treatment options to improve clinical outcomes. J Clin Psychiatry 1998, 59(Suppl. 1):3.
7. Weiden, P., Aquila, R., Standard, R.N. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996, 57(Suppl. 11): 53-60.
8. Goldstein, J.M. Preclinical profile of Seroquel (quetiapine): An atypical antipsychotic with clozapine-like pharmacology. In: Breaking Down the Barriers. Holliday, S.G., Ancill, R.J., MacEwan, G.W. (Eds.). John Wiley & Sons: London 1996, 177-207.
9. Casey, D.E. "Seroquel" (quetiapine): Preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs 1996, 5: 939-57.
10. Saller, C.F., Salama, A.L. Seroquel: Biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993, 112: 285-92.
11. Migler, B.M., Warawa, E.J., Malick, J.B. Seroquel: Behavioral effects in conventional and novel tests for atypical antipsychotic drugs. Psychopharmacology 1993, 112: 299-307.
12. Goldstein, J.M. Preclinical tests that further distinguish the pharmacological properties of a clozapine-like atypical antipsychotic. In: Dopamine Disease States. Beninger, R.J., Paloma, T., Archer, T. (Eds.). Editorial CYM: Madrid 1996, 299-306.
13. Carey, G., Bergman, J. Discriminative stimulus effects of proposed atypical neuroleptics in clozapine-trained squirrel monkeys. Behav Pharmacol 1994, 1: 114.
14. Swerdlow, N.R., Zisook, D., Taaid, N. "Seroquel" (ICI 204,636) restores prepulse inhibition of acoustic startle in apomorphine-treated rats: Similarities to clozapine. Psychopharmacology 1994, 114: 675-8.
15. Swerdlow, N.R., Bakshi, V., Geyer, M.A. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 1996, 279: 1290-9.
16. Robertson, G.S., Matsumura, H., Fibiger, H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994, 271: 1058-66.
17. Ellenbroek, B.A., Lubbers, L.J., Cools, A.R. Activity of "Seroquel" (ICI 204,636) in animal models for atypical properties of antipsychotics: A comparison with clozapine. Neuropsychopharmacology 1996, 15: 406-16.
18. 2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology 1998, 135: 119-26.
19. Thyrum, P.T., Fabre, L.F., Wong, Y.W.J., Ewing, B.J., Yeh, C. Multiple-dose pharmaco-kinetics of ICI 204,636 in schizophrenic men and women. Psychopharmacol Bull 1996, 32: 525A.
20. Quetiapine fumarate. Seroquel® package insert. Zeneca Pharmaceuticals 1997.
21. McConville, B. Pharmacokinetics, tolerability and clinical effectiveness of quetiapine fumarate in adolescents with selected psychotic disorders. 38th Annu Meet New Clin Drug Eval Unit Program (June 10-13, Boca Raton) 1998.
22. Wong, Y.W., Ewing, B.J., Thyrum, P.T., Yeh, C. Multiple-dose pharmacokinetics of "Seroquel" (quetiapine) in schizophrenic men and women. Schizophr Res 1997, 24: 200.
23. Thyrum, P.T., Jaskiw, G., Fuller, M., Wong, Y.W.J., Ewing, B.J., Yeh, C. Multiple-dose pharmacokinetics of ICI 204,636 in elderly patients with selected psychotic disorders. Psychopharmacol Bull 1996, 32: 524A.
24. Wong, Y.W., Ewing, B.J., Thyrum, P.T., Yeh, C. Pharmacokinetics of "Seroquel" (quetiapine) in hepatic and renal insufficiency. Schizophr Res 1997, 24: 200.
25. Grimm, S.W., Stams, K.R., Bui, K. In vitro prediction of potential metabolic drug interactions for Seroquel. Schizophr Res 1997, 24: 198.
26. Weiden, P. Quetiapine ("Seroquel"): A new antipsychotic. J Pract Psychiatr Behav Health 1997, 3: 368-73.
27. Wong, Y.W., Ewing, B.J., Thyrum, P.T., Yeh, C. The effect of phenytoin and cimetidine on the pharmacokinetics of Seroquel. Schizophr Res 1997, 24: 200-1.
28. Wong, Y.W., Ewing, B.J., Thyrum, P.T., Yeh, C., Potkin, S.G. Effects of haloperidol, risperidone, and thioridazine on the pharmacokinetics of quetiapine. Psychopharmacol Bull 1997, 33: 605.
29. Potkin, S.G., Thyrum, P.T., Bera, R. et al. Pharmacokinetics and safety of lithium co-administered with Seroquel (quetiapine). Schizophr Res 1997, 24: 199.
30. Borison, R.L., Arvanitis, L.A., Miller, B.G. and the US Seroquel Study Group. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996, 16: 158-69.
31. Small, J.G., Hirsch, S.R., Arvanitis, L.A., Miller, B.G., Link, C.G.G. and The Seroquel Study Group. Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997, 54: 549-57.
32. Arvanitis, L.A., Miller, B.G. and the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biol Psychiatry 1997, 42: 233-46.
33. Peuskens, J., Link, C.G. A comparison of que tiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997, 96 265-73.
34. Fleischhacker, W.W., Link, C.G. A multicenter double-blind, randomised comparison of dose and dose regimen of "Seroquel" in the treatment of patients with schizophrenia. 34th Annu Meet Am Coll Neuropsychopharmacol (Dec 11-15, San Juan) 1995.
35. Mullen, J., Reinstein, M., Bari, M., Ginsberg L., Sandler, N. Quetiapine and risperidone in outpatients with psychotic disorders: Results of the QUEST trial. 37th Annu Meet Am Col Neuropsychopharmacol (Dec 13-18, Sar Juan) 1998.
36. Meats, P. Quetiapine ("Seroquel"): An effective and well-tolerated atypical antipsychotic. Int J Psychiatry Clin Pract 1997, 1: 231-9.
37. Goldstein, J.M. Quetiapine fumarate: Effects on hostility and aggression in patients with acute schizophrenia. 38th Annu Meet New Clin Drug Eval Unit Program (June 10-13, Boca Raton) 1998.
38. Goldstein, J.M. Quetiapine fumarate: Effects on affective symptoms in patients with acute schizophrenia. 38th Annu Meet New Clin Drug Eval Unit Program (June 10-13, Boca Raton) 1998.
39. McManus, D.O., Arvanitis, L.A., Kowalcyk, B.B. and the Seroquel Trial 48 Study Group. Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders. J Clin Psychiatry 1999, 60: 292-8.
40. Juncos, J., Yeung, P., Sweitzer, D., Arvanitis, L., Nemeroff, C. Quetiapine improves psychotic symptoms associated with Parkinson's disease. 37th Annu Meet Am Coll Neuropsychopharmacol (Dec 14-18, Las Croabas, PR) 1998.
41. Schneider, L., Yeung, P., Sweitzer, D., Arvanitis, L.A. "Seroquel" (quetiapine fumarate) reduces aggression and hostility in patients with psychoses related to Alzheimer's disease. 152nd Annu Meet Am Psychiatr Assoc (May 15-20, Washington, DC) 1999.
42. Arvanitis, L.A., Rak, I.W. The long-term efficacy and safety of "Seroquel" (quetiapine). Schizophr Res 1997, 24: 196.
43. Satterlee, W., Dellva, M.A., Beasley, C., Tran, P., Tollefson, O. Effectiveness of olanzapine in long-term continuation treatment. Psychopharmacol Bull 1996, 32: 509.
44. Zborowski, J., Schmitz, P., Sebree, T. et al. An open-label assessment of the long-term safety of sertindole in the treatment of schizophrenia and other psychotic disorders. Eur Neuropsychopharmacol 1995, 5: 348A.
45. Hellewell, J.S.E. Attitudes towards the treatment of schizophrenia and perceptions of antipsychotics side effects: A multinational survey of psychiatrists, nurses, patients and care-givers. 11th Annu Cong Eur Coll Neuropsychopharmacol (Oct 31-Nov 4, Paris) 1998.
46. Hamner, M.B., Goldstein, J.M., Arvanitis, L.A., Cantillon, M. Quetiapine and prolactin: Low incidence of side effects referable to hyperpro-lactinemia is consistent with quetiapine's minimal effects on plasma prolactin. 151st Annu Meet Am Psychiatr Assoc (May 31-June 3, Toronto) 1998.
47. Goldstein, J.M., Cantillon, M. Low incidence of reproductive/hormonal side effects with "Seroquel" (quetiapine) is supported by its lack of elevation of plasma prolactin concentrations. 21st CINP Cong Glasgow, (July 12-16, Glasgow) 1998, Abst PT07093.
48. Miller, P.R., Cutten, A.E. Haematological side effects of clozapine: Patient characteristics. NZ Med J 1997, 110: 125-7.
49. Olanzapine. Zyprexa® package insert. Eli Lilly & Co. 1996.
50. Risperidone. Risperdal® package insert. Janssen Pharmaceutica 1996.
51. Feldman, J. Clozapine and agranulocytosis. Psychiatric Ser 1996, 47: 1177-8.
52. Cutler, A., Goldstein, J.M., Cantillon, M. Dosing and switching strategies for a dibenzothiazepine, a new class of atypical antipsychotic. Submitted.
53. Smith, D., Pantelis, C., McGrath, J., Tangas, C., Copolov, D. Ocular abnormalities in chronic schizophrenia: Clinical implications. Aust NZ J Psychiatry 1997, 31: 252-6.
54. Jaanus, S.D. Drug-related cataract. Optom Clin 1991, 1: 143-57.
55. Nasrallah, H.A., Dev, V., Rak, I., Raniwalla, J. One year of quetiapine availability - Any evidence of cataract risk? 152nd Annu Meet Am Psychiatr Assoc (May 15-20, Washington, DC) 1999.
56. Weiden, P.J. Medication noncompliance in schizophrenia: Part I. Assessment. J Pract Psychiatr Behav Health 1997, 3: 106-10.
57. Kalali, A., Hellewell, J., Goldstein, J., Langham, S. A multinational survey of patients' satisfaction with long-term "Seroquel" (quetiapine fumarate). 21st CINP Cong (July 12-16, Glasgow) 1998.
58. Weiden, P.J., Aquila, R., Standard, J.M. Switching antipsychotic medications. J Clin Psychiatry 1997, 58(Suppl. 10): 1-10.
59. Goldstein, J. Safety and tolerability of switching from conventional antipsychotic therapy to quetiapine fumarate followed by abrupt withdrawal from quetiapine fumarate. 38th Annu Meet New Clin Drug Eval Unit Program (June 10-13, Boca Raton) 1998.
60. Physicians' Desk Reference. Medical Economics: Montvale 1999.
61. Zimbroff, D.L., Kane, J.M., Tamminga, C.A. et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997, 154: 782-91.
62. Davies, A., Adena, M.A., Keks, N.A., Catts, S.V., Lambert, T., Schweitzer, I. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clin Ther 1998, 20: 58-71.
63. Sanger, T.M., Lieberman, J.A., Tohen, M., Grundy, S., Beasley, C., Tollefson, G.D. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999, 156: 79-87.
64. Chouinard, G., Jones, B., Remington, G. et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of schizophrenia. J Clin Psychopharmacol 1993, 13: 25-40.
65. Miller, C.H., Umbricht, D., Woerner, M., Fleischhacher, W.W., Lieberman, J.A. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998, 59: 69-75.
66. Peacock, L., Solgaard, T., Lublin, H., Gerlach, J. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology 1996, 124: 188-96.
67. Haloperidol. Haldol® package insert. Janssen Pharmaceutica 1996.
68. Dickson, R.A., Dalby, J.T., Williams, R., Edwards, A.L. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am J Psychiatry 1995, 152: 1102-3.
69. Tran, P., Hamilton, S., Kuntz, A. et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997, 17: 407-18.
70. Meltzer, H.Y., Goode, D.J., Schyve, P.M., Young, M., Fang, V.S. Effect of clozapine on human serum prolactin levels. Am J Psychiatry 1979, 136: 1550-5.
71. Lieberman, J.A. Maximizing clozapine therapy: Managing side effects. J Clin Psychiatry 1998, 59(Suppl. 3): 38-43.
72. Toth, P., Frankenburg, F.R. Clozapine and seizures: A review. Can J Psychiatry 1994, 39: 236-8.
73. Perkins, D.O. Weight gain and the new antipsychotics. J Psychotic Disord 1998, 2: 8-9.
74. Wirshing, D.A., Spellberg, B.J., Erhard, S.M., Marder, S.R. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998, 44: 778-83.
75. Goldstein, J.M. The new generation of antipsychotic drugs: How atypical are they? In: Novel Therapeutic Strategies in Schizophrenic and Bipolar Disorders. Racagni, G. (Ed.). Int Acad Biomed Drug Res: Milan, in press.
76. Goldstein, J.M. Atypical antipsychotic drugs: Beyond acute psychosis. Emerging Drugs 1999, 4: 127-52.